The following are the sponsors and partners supporting the ChinaBio® Investor Forum 2012 - Beijing. Our thanks to all of these top-tier organizations for helping make this event possible. For more information on how you can sponsor this or other ChinaBio's events, please contact Tom Wu.


China-Finland Golden Bridge is a service platform for Chinese investors and high-tech companies looking for investment and expansion opportunities in European market. Golden Bridge supports Chinese VCs in lead generation, in transaction process as well as in partnering and syndication. Being a connector to technology hubs in Finland, Golden Bridge increases visibility and provides access to innovation resources for Chinese VCs.
Golden Bridge is headquartered in Finland and has a collaboration and allocated resources e.g. in Shanghai, Shenzhen and Beijing. Golden Bridge is supported by MOFCOM, Chinese ministry of finance and TEM, Finnish ministry of Employment and the Economy.

Z-park Daxing Bio-medicine Industry Park, i.e. Beijing E-town Bio-medicine Industry Park (CBP) was established in 2005 with a planning area of 9.63 square kilometers. CBP is a biotechnology industrialization base established by Beijing municipal government for the revitalization of modern manufacturing. It undertakes the core function of developing the industries of Beijing biological technology independent innovation, product R&D, project incubation and technology industrialization, R&D and manufacture services etc. CBP enjoys a convenient traffic; it is located at the southwest conjunction of Jingkai Express Highway and Southern 6th Ring Road, surrounded by many railways and express highways of Beijing-Kowloon, Jingguang railway and Beijing-Shanghai, Beijing-Zhuhai Highway etc. Metro Line 4 has 2 stops in CBP, and the second International Capital Airport will be set up within 15km southeast to the Park. www.bjcbp.com.cn

Gold Sponsors

Suzhou BioBay is located in southwest of Suzhou Industrial Park, and is the key driver of life science innovation for Suzhou Industrial Park. Suzhou Industrial Park is has built into a garden city and modern high-tech city. More than 200 high-tech innovative companies covering drug discovery, diagnostic, medical device and CRO/CMO have been located in BioBAY, as well as Cold Spring Harbor Asia Conference Center, and 5000 scientists and professionals have come to join this dynamic innovative community. www.biobay.com.cn

Foley is a highly regarded, international law firm providing client-focused, industry-specific services that result in high-value legal counsel for our clients. Our practice areas encompass the full range of corporate legal services. With an office located in Shanghai, the attorneys of Foley’s China Practice are well positioned to assist U.S., Asian, and European clients with the complex matters that arise when doing business in or related to Greater China. From IP procurement and technology transfer to M&A due diligence, count on Foley’s experience and our cultural and business connections in China to help you stake you claim. www.foley.com

Johnson & Johnson is a broad-based company with a strong vision, a culture of caring, and the resources to invest in the future to take the health and well being to a new level for people throughout the world. Janssen Pharmaceutical China R&D and SA is a major hub in Johnson & Johnson’s family of pharmaceutical focused R&D organizations. Our vision is to be a first-class research and development group capable of efficiently and effectively discovering, developing, and registering innovative healthcare solutions for patients in China, Asia-Pacific region and worldwide. www.jnj.com.

Legend Capital (LC) is a venture capital firm with over USD$1.5 billion and RMB3.5 billion funds under management. Consistently ranked among the top five in China, LC has offices in Beijing, Shanghai and Wuhan. By January 2012, LC had invested in over 150 companies, of which 20 are listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, GEM and ChiNext of Shenzhen Stock Exchange, and another 11 had achieved exit through M&A. LC has an investment team with over 50 professionals, including 14 partners. LC has invested in close to 20 healthcare and life sciences companies, such as Kingmed, Pharmaron, EverCare, AmCare, YiXinTang, Kawin Technology and Dihon Pharmaceutical. Aggressively seeking investment opportunities in this sector, LC has a healthcare-dedicated team with eight investment professionals. www.legendcapital.com.cn

From concept to commercialization and through exit, Morrison & Foerster's global Life Sciences Group is recognized as a leading provider of comprehensive legal services to the life sciences industry and its funding sources. The unique strength of our practice is in our ability to meld hands-on scientific acumen with deep business and legal insight. With offices in Shanghai, Beijing, and Hong Kong, as well as Tokyo, Europe and across the United States, Morrison & Foerster is incomparably positioned to assist life sciences entities around the world. For more information, please visit www.mofo.com.

Official Partners

BayHelix is an organization of leaders of Chinese origin in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by invitation only. www.bayhelix.org

BioCentury Publications, Inc., www.biocentury.com provides essential biopharma industry intelligence from five offices in the U.S. and Europe. For more than 18 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship BioCentury, the Bernstein Report on BioBusiness; SciBX: Science-Business eXchange, a translational science joint publishing venture with Nature Publishing Group; and BioCentury Extra, online daily news covering breaking developments BioCentury also markets its BCIQ: BioCentury Online Intelligence, an online business intelligence resource. In September 2010, the company launched BioCentury This Week, the first weekly biotech public affairs TV program to be broadcast in major U.S. television markets, a partnership with the Gannett-owned CBS affiliate W*USA Channel 9 in Washington, D.C. The BioCentury This Week TV show website continuously streams TV content at www.biocentury.com.

Business Wire is a trusted partner to thousands of Health, Medical, Biotech and Pharmaceutical companies and organizations throughout the world, delivering more corporate news releases from more sources to more destinations than any other service. Business Wire's news wire circuits enable you to target your news to select audiences based on your geographic and industry market needs. Business Wire is the only commercial news wire with full-carriage access to all of the world's leading news agencies, including the Associated Press, Agence France-Presse, Dow Jones, Reuters, Jiji Press, Interfax and more. We can send your news to virtually any media market in the world with distribution to more than 150 countries in dozens of local languages. From delivery to audiences in a single city to comprehensive worldwide coverage including translations, Business Wire offers you an easy, one-stop solution. www.businesswire.com

VC Partners

Cenova Ventures, founded in 2009 and located in Shanghai, is dedicated to China life sciences and healthcare investment. We primarily focus on emerging and growing companies with significant market potential in China life sciences sectors, including pharmaceuticals, biotech, medical devices, diagnostics, and healthcare services.
The Cenova Venture Fund is managed by seasoned life science investment professionals, and the investment team combines experiences of successful venture start-up and venture investment, management of pre- and post-IPO companies, with proven capabilities to leverage global perspectives, local experiences and network to develop and implement business strategies that best fit specific situations in China. The team has established extensive relationships and network in life science sectors both in the West and in China, including leading hospitals and key opinion leaders, various government agencies, senior industry executives, overseas Chinese professionals, academic community, and investment community. www.cenovaventures.com

Decheng Capital is a leading China venture capital firm that provides capital to early and growth stage life science companies. We are a team of investment professionals with complementary expertise, a long history of working together and a shared dedication to building highly successful companies that span the full spectrum of the life sciences industry. Our domain knowledge, access to innovative technologies and ability to bring proven Western products to China make us the preferred partner for entrepreneurs, domestic and multinational companies, government agencies and investors. Decheng Capital is poised to capitalize on a historic opportunity in China’s rapidly developing life sciences industry and to deliver superior returns for our investors. www.decheng.com

Fidelity Asia Ventures (FAV) is the Asian venture capital arm of FIL Limited, part of the global Fidelity Investments organization. Fidelity Investments is one of the largest mutual fund organizations in the world, managing assets in excess of $1.5 trillion globally.
FAV's mission is to invest in high-quality, high-growth companies broadly in the information technology, healthcare, and consumer sectors in China. FAV has offices in Hong Kong, Beijing, and Shanghai, and a successful track record of investing in leading companies within their respective industries. Current investments and recent exits include: Alibaba (HKSE: 1688), AsiaInfo (NASDAQ: ASIA), Wuxi PharmaTech (NYSE: WX), Hurray! (NASDAQ: HRAY), Linktone (NASDAQ: LTON), Xunlei, and iSoftstone etc. For more information, please visit: www.fidelityasiaventures.com

Kaiwu Capital is a venture capital firm managed by a group of successful entrepreneurs, experienced investors and corporate executives. We focus on broad sectors including Technology, Media & Telecom (TMT), Clean-tech, Healthcare, New materials, Renewable energy, Consumer and Education. We look to invest in fundamentally solid companies with great “DNA” and long-term growth potential, companies that we can be proud of 20 years from now. Our team has developed strong reputations through many years of investment and entrepreneurial experience and will apply this knowledge towards supporting Kaiwu portfolio companies to achieve long-term success. www.kaiwucapital.com

KPCB (Kleiner Perkins Caufield & Byers) is a world leading venture capital firm established in 1972 and headquartered in Silicon Valley. Since its establishment 40 years ago, KPCB has invested in over 500 start-ups, and some of them are world renowned companies such as Google, AOL, Amazon, Netscape, ompaq, Electronic Arts, Sun Microsystems, and America's largest biomedical technology company Genetech. KPCB China was founded in 2007. It currently manages funds totaling approximately 800 million US dollars, and co-manages a fund of funds totaling approximately 4 billion US dollars with KPCB US to support Chinese entrepreneurs and to promote innovation in high-growth industries. KPCB’s focus industry sectors include TMT, green tech, life science and advanced consumer goods & services. KPCB China team has invested in considerable amount of very successful companies such as Alibaba, Baidu, China Netcom, Focus Media, Hurray, CGEN, A8 Music, Venustech, Autonavi, Kanghui Medical, Sungrow, China Auto Rental, and Sinosun etc. www.kpcb.com/china

Legend Capital (LC) is a venture capital firm with over USD$1.5 billion and RMB3.5 billion funds under management. Consistently ranked among the top five in China, LC has offices in Beijing, Shanghai and Wuhan. By January 2012, LC had invested in over 150 companies, of which 20 are listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, GEM and ChiNext of Shenzhen Stock Exchange, and another 11 had achieved exit through M&A. LC has an investment team with over 50 professionals, including 14 partners. LC has invested in close to 20 healthcare and life sciences companies, such as Kingmed, Pharmaron, EverCare, AmCare, YiXinTang, Kawin Technology and Dihon Pharmaceutical. Aggressively seeking investment opportunities in this sector, LC has a healthcare-dedicated team with eight investment professionals. www.legendcapital.com.cn

Lilly Ventures is the venture capital arm of Eli Lilly and Company, a leading innovation-driven pharmaceutical company. Our primary goal is to facilitate the success of companies in our areas of focus through early to expansion stage investments and value-adding resources.
Lilly Ventures currently has $175 million under management and focuses on three major areas of interest.
Biotechnology: targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a robust pipeline.
Medical Technology: targeting investments in companies focusing on the convergence of pharmaceuticals, devices or diagnostics.
Healthcare IT: targeting investments in start-up companies with innovative network technologies that promise to have a transformational impact on the current pharmaceutical business model.
Our investment approach centers on working with superior management teams to help them realize the financial potential of their ideas. Accordingly, we provide both financial and intellectual resources to accelerate the management teams’ path to success. Our sister fund, Lilly Asian Ventures, was established in 2007 with a geographic focus on the emerging life science businesses of east and south Asia, particularly China and India. www.lilly.com

Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. The Chan family founded the Hang Lung Group in Hong Kong in 1960. Morningside engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. Morningside was one of the earliest institutional investors in China's internet industry and in recent years has been a leader in China's emerging biotechnology sector. In China's media sector, Morningside has been active in both outdoor and print media. www.morningside.com.cn


OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm, with over $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 100 private companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes approximately 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed’s professionals work together using a collaborative, team-oriented approach to support our portfolio companies, which has earned OrbiMed a reputation as a capital provider of choice for life sciences companies of all stages. OrbiMed has created the first pan-Asia healthcare and life sciences-dedicated venture capital fund, with close to $200M under management. OrbiMed’s headquarters are in New York City and has offices in Shanghai and Mumbai. www.orbimed.com

Orchid Asia Group Management, Limited ("Orchid Asia Group") is an investment group with offices in Hong Kong, Shenzhen, Shanghai, Beijing and Guangzhou. We focus on backing experienced executives in building franchises in Asia, with an emphasis in China. We seek to invest in expanding domestic enterprises in high barrier to entry businesses that have good growth prospects in the consumer services and products sector, as well as the outsourced manufacturing and services sector. Orchid Asia Group manages funds with investment partnerships that have capital commitments globally from groups of leading institutional investors, independent private banks, university endowments, insurance companies, strategic individual capitalist and high net worth family offices. www.orchidasia.com

Sequoia Capital was established in 1972 and was one of the oldest and most reputable Funds in the U.S. In the last 30 years of high-tech industry's rise in the US, Sequoia has backed almost all the leading breakthrough companies as the first institutional investor. Such companies include Apple Computer, Cisco, Oracle, Yahoo, Google, etc. Sequoia invested companies consist more than 20% of NASDAQ's entire market value. Sequoia Capital China’s LPs are top US universities’ endowments, world-class foundations and investment institutions. www.sequoiacap.com

Tsinghua Science Park Venture Capital, also named as TusPark Ventures or TusPark Capital, is the venture investment arm of Tsinghua Science Park. Affiliated with Tsinghua University, Tsinghua Science Park is ranked the best university owned Science Park in China to promote technology innovation and entrepreneurship.
Founded in March 2001, Tuspark Ventures now manages over 300M USD capital and assets, which focus on early-stage, hi-tech investment. By leveraging TusPark’s world-class incubation experience, facilities and resources, “VC+Incubation” has been developed by TusPark Ventures as the best practice business model in China. Over the past 10 years, Tuspark Ventures has invested over 50 portfolio companies, which covers TMT, Bio-Tech, Clean-Tech and other industrial sectors. Some of them have been listed in either Nasdaq or local stock exchange, and had realized promising financial returns to our investors. Tuspark Ventures’ experience proves that our business model does provide the multi-WIN scenario for entrepreneurs, investors, government, university, industries and ourselves as fund managers.


WI Harper Group works with entrepreneurs who target growth opportunities in Greater China as a key objective for their business. WI Harper pioneered the concept of building a business bridge across the Pacific Ocean for early stage IT and life sciences companies. Since 1996, we have backed over 90 emerging companies in China, Taiwan and the United States, resulting in 15 IPOs and a number of M&A transactions. Our investment professionals in Beijing, San Francisco and Taipei manage over $400M in assets. WI Harper currently manages six funds totaling over US$400 million from its headquarters in San Francisco and branch offices in Beijing, Taipei, and Singapore. WI Harper's portfolio includes over 90 companies in high-growth areas of information technology and life sciences. WI Harper's list of successful portfolio companies currently include examples such as Focus Media (NASDAQ: FMCN), ISSI (NASDAQ: ISSI), iKang, DivX (NASDAQ: DIVX), Commerce One, Bridge Pharmaceutical, Cardiva Medical, PC Home, Kuro, Silicon Motion (NASDAQ: SIMO), Beijing Xinwei, Verisilicon, China Broad Media, MAXTHON, HomeE, Panorama Stock, 3G Portal, Mapbar and Laszlo etc. The firm's previous investments include with companies such as Creative Technology, CommerceOne, Intraware, S3, ISSI and many other public companies. www.wiharper.com

Supporting Partners

BIOCOM is a leading biotechnology industry association with over 550 leading life science companies from Southern California as members. BIOCOM's initiatives focus on capital formation, public policy, resource development and scientific discovery and development. They have recently launched a special program to educate and connect U.S.-based life science companies with low cost resources and services available in China. www.biocom.org

BioStar Consulting is a professional investment and financial firm focusing on biomedical field; we provide high quality professional services for Beijing municipal government, domestic and international biomedical companies as well as venture capital institutions. With global perspective, we serve as a bridge for a better communication between Beijing municipal government and biomedical companies. Our mission is to help Chinese biopharmaceutical companies to become industry leaders, and to facilitate Chinese enterprises to go to the world. www.bjbiostar.com

Beijing Pharma and Biotech Center (BPBC) is the principal health research agency of the Beijing Local Government; it is a component of Beijing Municipal Commission for Science and Technology (BMCST). Established in 1996 and initially function as the development and implementation of Beijing Government Grants Policy, BPBC serves as the focal point for advisory industrial policy, mandatory project management for government and international bridge between Chinese Biotech & Pharmaceutical Industry and the rest of the world. BPBC is composed of five divisions: Project Management, Strategy Study, Business Liaison and International Affairs, General Administration and Financial Management Divisions. www.newlife.org.cn

Chinese-American BioPharmaceutical Society (CABS) is a not-for-profit, non-political, non-religious professional organization headquartered in San Francisco, California. With the rapid development of bio/pharmaceutical industry in China, more and more people, regardless of their ethnic backgrounds, are looking toward China for business and scientific opportunities. Recognizing this trend, CABS was established not only to educate the public with the progress in biotech and pharmaceutical fields, but also to serve the Bio/Pharmaceutical professionals who are either with Chinese heritage or with professional interests in China. The majority of CABS members are Chinese scientists, entrepreneurs and students/postdocs in biomedical sciences, working in San Francisco Bay Area bio/pharmaceutical industries, universities, and research institutes. The CABS membership is open to the public. www.cabsweb.org

The Chinese Biopharmaceutical Association (CBA) is a non-profit organization made up of professionals who have an interest in bio-pharmaceutical research and/or technology development. CBA was established in 1995 and its headquarters are located in the State of Maryland, which is adjacent to the U.S. capital city of Washington D.C. The majority of CBA members are Chinese scientists, researchers, or professors. They work in government agencies, universities, research institutes as well as in the biotechnology and pharmaceutical industries. Some are conducting pioneering research with the National Institutes of Health (NIH), whereas others are directly involved in the government regulatory process as officers of the Food and Drug Administration (FDA) or in the field of intellectual property as patent attorneys or as patent examiners with the Patent and Trademark Office (PTO). www.cba-usa.org

Cyagen Biosciences was established to develop technologies in stem cell research, genetic engineering and transgenic animal research to serve the growing needs from life sciences labs and drug discovery companies. The principals of Cyagen consist of world-class scientists, senior industry experts and professional managers from both the U.S. and China. Cyagen's 1600 square meter main R&D and production facility is located in the Science City on the outskirt of Guangzhou, encompassing a laminar flow ultra-clean cell culture lab built to GMP standard, a molecular biology lab, and an animal barrier facility housing mice and rats intended for transgenic and gene knockout research. The business philosophy of Cyagen is to create a competitive advantage by marrying cutting-edge technologies in the U.S. with cost effectiveness R&D in China, and to use this advantage to bring top-quality reagents, tools and services to researchers around the world at favorable prices. www.cyagen.com

Guangzhou Biotechnology Center (namely Biomedical work group of Guangzhou Municipal Government) under the jurisdiction of the Biotechnology Steering Group and the Sciences &Technology Bureau of Guangzhou Municipal Government is a service agency specializing in biotechnology and medicine industry. Its key missions are to develop the biotechnology and medicine industry of Guangzhou and to accelerate the transfer of S&T achievements and parallel cooperation and exchange. www.gzbio.net

Hong Kong Science and Technology Parks Corporation (HKSTP) is a statutory body set up by the Government of the Hong Kong SAR to promote and facilitate the transformation of Hong Kong into Asia’s hub for technology innovation. The Corporation supports a number of technology industries engaging in cutting-edge research and development, including the Life Science and Biotechnology industries, and offers a comprehensive range of facilities and services to address the needs of companies at various stages of development. www.hkstp.org

Lychee Group is a media company specializing in the organization of high-end business-to-business events for China's life sciences industry. We have launched some of the highest-profile events in China including, “CHINATRIALS: Global Clinical Development Summit” and “China Healthcare Investment Conference,” both the largest events in China of their kind. Our mission is simple: create the best, most innovative events to provide our attendees with the latest business information and the greatest opportunity to network with peers and new potential business partners. www.lycheegroup.com

Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA) is a 501(C) (3) nonprofit organization founded in early 2002 by professionals and scholars from local Chinese community in San Diego. We invite all scholars, students and professionals with any origin who are working in, engaged in, or interested in the biotech and pharmaceutical industry to join us as members of SABPA. www.sabpa.org

The Sino-American Pharmaceutical Professionals Association (SAPA) was founded in 1993 as a non-profit organization with its headquarters in the Greater New York area (NJ/NY/CT). SAPA has grown rapidly to become one of the most active and well-recognized professional organizations in the United States with over 4000 members. SAPA's missions are to facilitate the advancement of pharmaceutical science and biotechnology, to contribute to public health education, to foster personal and professional career development, and to promote scientific exchange and business cooperation between the USA and China. In addition to the Greater New York area, SAPA has established regional chapters in New England (SAPA-NE), Greater Philadelphia (SAPA-GP) and West Coast (SAPA-WEST), as well as Shanghai Club (SAPA-Shanghai). www.sapaweb.org

Media Partners

Bioon is the leading life science portal in China. And professional registered members have more than 500 thousand; special 70% members are the master's -and doctoral qualifications. Our enterprises’ customers are more than 11 thousand, such as Invitrogen, Promega, Qiagen, Sigma, Pall. As the leading service- provider in China, we are committed to enhance the competition of our customers in life sciences. The following pipelines are our mature businesses: (1) www.bioon.com commitment to the field of life sciences media and brand promotion; (2) www.bioon.com.cn focused on our customers’ products -promotion, display and rankings, such as equipments, consumables, reagents and antibodies; Addition, we collected and sorted the serial of databases -including China lab database, professor database and region -based registered members database. These databases are the strong support and tool for customers marketing activity and marketing survey & analysis. Now, Bioon.com has become the preferred options to life sciences’ customers for professional seminar & training, targeting product promotion, brand -improvement and marketing survey & analysis. of professional customers in China. www.bioon.com

China is already the fastest growing market in the world for pharmaceuticals. Now, after billions of dollars of government and private investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today focuses exclusively on the rapidly evolving biotech industry in China. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China biotech companies and industry events, as well as global issues affecting the China market. www.chinabiotoday.com

Essinova Life Science TV is an Internet TV channel and community for life sciences, biopharma, medical devices and healthcare services industries. We produce and publish executive interviews, corporate videos, investor pitches, product demos, science and technology visualization, event videos and other multimedia content serving companies and organizations in business for health. Our program brings fresh perspectives, candid insights, unique stories and practical expertise to our viewers. Our creative and broadcast-quality productions showcase innovative ideas, technologies, products and methodologies for our clients more compellingly than any conventional media. We help our clients and members deliver their messages to their desired audience efficiently and cost-effectively, utilizing the power of rich and social media, and leveraging our growing network of partnerships. www.essinova.com

Healthcare Executive, established in December 2008, is a monthly magazine focused on the pharmaceutical industry. It is hosted by Chinese Pharmaceutical Enterprises Association and ZhuoXin Medical Media Group and supported by a team consists of senior medical media people, and positioned to a “the news and resource center in the pharmaceutical industry”. Its readers are mostly entrepreneurs, investors, and people work at the supervision and services organizations in this industry.
In terms of the content, Healthcare Executive has been realistic, reports on the whole industry chain, discovers the experiences and concerns, strategies and execution, growth and missions of industry entrepreneurs and forms the most abundant and comprehensive database of the growth cases of the industry companies. It combines global vision and local intelligence, being open-minded and concentrated at the same time, brings the most and profound understanding to its readers, building new medical media languages. Healthcare Executive also presents the first hand industry news on the development of new products, production and circulation, supervision and services organizations, capitals, helps people update information quickly, discover values and make progress. Our vision is that every one serves in pharmaceutical industry reads Healthcare Executive. For now, we’re working hard to make each issue a great excitement. www.he-cn.com

Interfax China is a member of the Interfax International Information Group. Interfax Group provides news and other information products that are essential for decision-makers in politics and business. Since early 1990s, Interfax has been the main provider of up-to-date news from Russia and countries of the former Soviet Union. We are the most frequently quoted source of information on the region. Over the past few years, Interfax has also become a leading provider of political and business news from China and emerging markets of Central Europe. www.interfax.cn

PEDaily.cn is a leading web portal in the venture capital and private equity industry in China. Integrating the strongest networks and research resources of Zero2IPO Group, PEdaily.cn focuses on sharing timely industry news, abundant data, and in-depth analysis with its users. www.pedaily.cn

PharmAsiaNews.com is an online portal providing news and analysis on regulatory, legal and financial developments affecting pharmaceutical, biologics and medical device manufacturers doing business in China, India, Japan and other nations of the Pacific Rim. PharmAsiaNews.com leverages the editorial excellence of "The Pink Sheet" -- the leading information source for the U.S. pharmaceutical industry since 1939. Subscribers get original on-the-ground reporting from news bureaus across Asia, guest columns, exclusive interviews, news summaries, English translation summaries of Chinese- and Japanese-language news, and aggregated content from around the globe. Free 30-day trial. www.PharmAsiaNews.com

Pharma China is the most trusted English media and business intelligence service covering the Chinese pharmaceutical / biopharmaceutical industry and market. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most multinational pharmaceutical companies, leading CROs, investment banks and consulting firms active in China as well as relevant industry associations and government agencies.


Pharma Connections Worldwide® is a professional business networking and consulting company focused in the Pharmaceutical, Biotechnology, Medical Devices and Life Sciences industry. With contacts from over 130 Countries we are truly global. Visit these links for more information on our services and opportunities. www.pharmaconnections.com

For more sponsorship information , please contact:

Tom Wu
ChinaBio® LLC
Tel: +86 21 5137 0751 ext 15
Fax: +86 21 5137 1368
From USA: +1 858 926 4566 ext 15




Sponsors & Partners

Gold Sponsors
Official Partners
VC Partners
Supporting Partners
Media Partners